News

By capitalizing on CreaGen’s chemistry expertise and state-of-the-art laboratory facility, Empiriko is validating methodologies for its transformative Biomimiks technology. Now pharmaceutical customers, for the first time, can use

XBiotech will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries

iBio obtained an exclusive license to patents and related intellectual property for this novel therapy, and then entered a collaboration agreement with the Medical University of South Carolina

The NDA submission is based on a series of laboratory and clinical studies conducted by OptiNose in the US and Europe, including comparative bioavailability and phase II and

BAX 826 is a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness. The amended license

Additionally, Mayo’s Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The company said that the other two sites scheduled for the multi-center

The new contract is expected to increase both production and reduce production costs targeting increased sales volume and market share. Imatinib’s market in Russia for 2012 amounted to

Used by Genzyme for its internal product development and external sublicensing, the technology allows a gene therapy Adeno-Associated Viral vector (AAV) to package and deliver more potent therapeutic

Commenting on the investment, Penn Pharma chief executive officer Richard Yarwood said the move was fuelled by its demonstrated ability to provide pragmatic and timely solutions for their